Objective To investigate whether funding of drug studies by the pharmaceutical industry is
associated with outcomes that are favourable to the funder and whether the methods of trials …

Kefauver, Chairman of the United States Senate’s Anti-Trust and Monopoly Subcommittee,
put together the first extensive indictment against the business workings of the …

OBJECTIVES: We aimed to systematically review and assess published estimates of the
cost of developing new drugs. METHODS: We sought English language research articles …

Data indicate that the widely touted “innovation crisis” in pharmaceuticals is a myth. The real
innovation crisis, say Donald Light and Joel Lexchin, stems from current incentives that …

… In 2003 Lexchin and colleagues found that industry funded … with any other source of
sponsorship (Lexchin et al. 2003). … the evidence subsequent to the Lexchin article and found 17 …

… This decision was based on the poor reporting quality of data in letters and conference
abstracts encountered in a previous version of our review (Lexchin 2003). A comment to the …

Background Pharmaceutical companies spent $57.5 billion on pharmaceutical promotion in
the United States in 2004. The industry claims that promotion provides scientific and …

OBJECTIVE: To determine the effect of three types of interaction between physicians and
the pharmaceutical industry--company-funded clinical trials, company-sponsored continuing …

Background: Direct-to-consumer advertising (DTCA) of prescription drugs has increased
rapidly in the United States during the last decade, yet little is known about its effects on …

Only the United States and New Zealand allow advertising of prescription drugs directed at
patients. US spending on such advertising grew rapidly during the 1990s, reaching $2.47 bn (…